Trial reportThe American journal of clinical nutrition2026
Effects of 12-month probiotic supplementation on bone mineral density and bone turnover markers in early postmenopausal females: A double-blind randomized controlled trial.
Trial report in The American journal of clinical nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly postmenopausal females experience rapid bone loss, and modulation of the gut-bone axis has been proposed as a preventive strategy. However, the role of probiotics relative to established lifestyle factors such as nutrition and physical activity remains unclear.
objectivesTo evaluate whether 12 mo of supplementation with a lactobacilli-based probiotic attenuates bone loss in early postmenopausal females.
methodsIn this double-blind, randomized, placebo-controlled trial, 114 females 1 to 8 y postmenopause were allocated to a daily probiotic (Lactiplantibacillus plantarum DSM15312, DSM15313, and Lacticaseibacillus paracasei DSM13434) or placebo. The primary outcome was change in distal tibia total volumetric bone mineral density (BMD) assessed by high-resolution peripheral quantitative computed tomography. Secondary outcomes included additional high-resolution peripheral quantitative computed tomography parameters, areal BMD by dual-energy X-ray absorptiometry, and circulating biomarkers. Intention-to-treat analyses were conducted using linear mixed-effects models, adjusted for baseline covariates; secondary outcomes were corrected for multiple comparisons.
resultsA total of 114 participants were randomly assigned, and all available data were included in the analyses. Baseline characteristics were broadly comparable. Over 12 mo, both groups experienced modest declines in bone density. The primary analysis showed a modest but statistically significant greater decline in distal tibia total volumetric BMD in the probiotic group compared with placebo (-3.7 mg HA/cm
conclusionsIn early postmenopausal females, 12-mo supplementation with a lactobacilli-based probiotic does not attenuate bone loss and was associated with a small but statistically significant greater reduction at the primary site. These findings do not support this probiotic formulation as a standalone intervention for skeletal preservation. This trial was registered at the Australian and New Zealand Clinical Trials Registry as ACTRN12621000810819.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.